Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03836261
Title Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Acerta Pharma BV
Indications

chronic lymphocytic leukemia

Therapies

Bendamustine + Rituximab

Cyclophosphamide + Fludarabine + Rituximab

Acalabrutinib + Venetoclax

Acalabrutinib + Obinutuzumab + Venetoclax

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT

Additional content available in CKB BOOST